Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) shares have recently underperformed, declining -6.8% over the past month against broader market and industry gains, despite a history of consistently beating prior EPS estimates. While current quarter EPS is projected to decline 10.2% year-over-year, full-year 2024 EPS is expected to grow 6.4%, supported by robust revenue forecasts including a 6.7% rise for the full year. With a Zacks Value Style Score of B indicating it trades at a discount to peers, Amgen currently holds a Zacks Rank #3 (Hold), suggesting anticipated in-line market performance in the near term.

Analysis

Amgen Inc. (AMGN) presents a mixed fundamental picture, contributing to its recent market underperformance. Over the past month, the stock has declined 6.8%, lagging both the S&P 500 composite's 2.3% gain and its own industry's 3.6% rise. This price action reflects investor apprehension over near-term earnings, as consensus estimates for the current quarter project a 10.2% year-over-year decrease in EPS to $5.01. In contrast, the company has a strong track record of execution, having beaten EPS estimates for the last four consecutive quarters and revenue estimates in three of those periods. For the full current fiscal year, forecasts remain positive, with expected EPS growth of 6.4% and revenue growth of 6.7%. However, a significant deceleration is anticipated for the next fiscal year, with projected EPS and revenue growth slowing to just 1.2% and 1.6%, respectively, and associated estimates have been revised slightly downward. Despite the growth concerns, the stock appears attractively valued, earning a Zacks Value Style Score of 'B', indicating it trades at a discount to its peers. This combination of factors underpins its Zacks Rank #3 (Hold), suggesting its performance will likely mirror the broader market in the near term.

Key Decisions for Investors

• Given the conflicting signals of a discounted valuation against a projected near-term earnings decline and future growth deceleration, a neutral, market-weight stance is warranted, aligning with the stock's 'Hold' rating.
• Investors should closely scrutinize the upcoming quarterly earnings report to see if the company can outperform the consensus EPS estimate, which currently forecasts a significant 10.2% year-over-year decline.
• While the recent 6.8% share price drop and 'B' value grade may present an opportunity for value-oriented investors, the sharp deceleration in projected revenue growth to 1.6% for the next fiscal year is a key risk for growth-focused strategies.
• Pay close attention to revisions in consensus estimates for the next fiscal year, as the recent negative trend for both earnings and revenue forecasts represents the primary headwind for the stock's long-term performance.